Dr. Maurie Markman on the Further Study of PD-1 Inhibitors in Ovarian Cancer

Dr. Maurie Markman Developing Research Into Checkpoint Inhibitors in Ovarian CancerПодробнее

Dr. Markman on Precision Medicine in Ovarian CancerПодробнее

Dr. Maurie Markman on Targets for the Treatment of Ovarian CancerПодробнее

Dr. Markman on the Future of Treatment for Ovarian CancerПодробнее

Did You Know? The Importance of HRD Testing in Advanced Ovarian Cancer With Maurie Markman, MDПодробнее

Dr. Markman on Immune Targeting in Ovarian CancerПодробнее

Dr. Maurie Markman on the Phase III AURELIA Trial for Platinum-Resistant Ovarian CancerПодробнее

Dr. Maurie Markman on the PROFILE 1007 Crizotinib TrialПодробнее

Dr. Markman on Immune Targeting in Ovarian CancerПодробнее

Seminar Clips: PARP Inhibitors and BRRCA1/2 Cancers- Susan Domchek, MD | Stanford Cancer InstituteПодробнее

Dr. Markman Discusses the Olaparib Phase II TrialПодробнее

Dr. Markman on the Search for Actionable Biomarkers in Ovarian CancerПодробнее

Dr. Markman Discusses the Future of Treatment for Ovarian CancerПодробнее

AHNS Virtual Education: Indications of PD-1 Inhibitors for Advanced cSCCПодробнее

Dr. Markman on Endpoints in Clinical Trials for Ovarian CancerПодробнее

Dr. Markman on Combination Treatments in Ovarian CancerПодробнее

Cancer Treatment Centers of America: The Emergence of Precision Medicine with Dr. Maurie Markman, MDПодробнее

SOLO1: 7-Year Follow-up Highlights the Value of Maintenance OlaparibПодробнее

Immune adverse events of checkpoint inhibitorsПодробнее